Am-Pharma B.V.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for Chimeric alkaline phosphatase-like proteins (US 11,746,340) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Downstream Processing of an Alkaline Phosphatase (US 10,570,380) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,557,545 | Modified phosphatases In force · USPTO record | In force | USPTO record | |
| US 8,586,032 | Use of alkaline phosphatase in the treatment of reduced renal function In force · USPTO record | In force | USPTO record | |
| US 9,926,544 | Chimeric alkaline phosphatase-like proteins In force · USPTO record | In force | USPTO record | |
| US 10,822,597 | Chimeric alkaline phosphatase-like proteins In force · USPTO record | In force | USPTO record | |
| US 11,746,340 | Chimeric alkaline phosphatase-like proteins In force · USPTO record | In force | USPTO record | |
| US 12,534,713 | Chimeric Alkaline Phosphatase-Like Proteins In force · Low confidence | In force | Low confidence | |
| US 10,570,380 | Downstream Processing of an Alkaline Phosphatase In force · Medium confidence | In force | Medium confidence | |
| US 12,178,857 | Recombinant Alkaline Phosphatase for Use in Treating Sepsis-Associated Acute Kidney Injury In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 3 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 6 no status recorded
Showing 1 to 9 of 9, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/952,680 | Recombinant Alkaline Phosphatase for Use in Treating Sepsis-Associated Acute Kidney Injury | Nov 19, 2024 | Pending |
| 18/044,549 | Recombinant Alkaline Phosphatase for Use in Treating Acute Respiratory Distress Syndrome | Sep 9, 2021 | Abandoned |
| 16/560,608 | Downstream Processing of an Alkaline Phosphatase | Sep 4, 2019 | Abandoned |
| 16/127,159 | Sep 10, 2018 | No status recorded | |
| 15/009,077 | Jan 28, 2016 | No status recorded | |
| 14/665,846 | Mar 23, 2015 | No status recorded | |
| 14/020,269 | Sep 6, 2013 | No status recorded | |
| 14/124,338 | Jun 8, 2012 | No status recorded | |
| 12/231,028 | Aug 27, 2008 | No status recorded |